FAQ

PSMA-617

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2015-2017
051020152017

Related topics

Related topics

1 relation

Broader (1)

Dipeptides

Related mentions per year

Related mentions per year

1937-2018
19401960198020002020
PSMA-617
Dipeptides

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients.
177Lu-labeled PSMA-617 is a promising new therapeutic agent for radioligand therapy (RLT) of patients with metastatic castration… (More)
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
Is this relevant?
2017
2017
44Sc-PSMA-617 for radiotheragnostics in tandem with 177Lu-PSMA-617—preclinical investigations in comparison with 68Ga-PSMA-11 and 68Ga-PSMA-617
BACKGROUND The targeting of the prostate-specific membrane antigen (PSMA) is of particular interest for radiotheragnostic… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
2017
2017
Preclinical Evaluation of 18F-PSMA-1007, a New Prostate-Specific Membrane Antigen Ligand for Prostate Cancer Imaging.
In recent years, several radiotracers targeting the prostate-specific membrane antigen (PSMA) have been introduced. Some of them… (More)
Is this relevant?
2016
2016
PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617.
UNLABELLED Prostate-specific membrane antigen (PSMA) is an excellent target for radionuclide therapy of metastasized castration… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2016
2016
225Ac-PSMA-617 for PSMA-Targeted α-Radiation Therapy of Metastatic Castration-Resistant Prostate Cancer.
Prostate-specific membrane antigen (PSMA) is a promising target in prostate cancer. Recently, we started the first-in-human… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2016
2016
18F-Labelled PSMA-1007 shows similarity in structure, biodistribution and tumour uptake to the theragnostic compound PSMA-617
The biochemical and radiological responses to radionuclide therapy with Lu-PSMA-617 targeting prostate-specific membrane antigen… (More)
Is this relevant?
2016
2016
Positive Influence of 177Lu PSMA-617 Therapy on Bone Marrow Depression Caused by Metastatic Prostate Cancer.
A 75-year-old man with castrate-resistant prostate cancer and increasing prostate-specific antigen (PSA) level developed severe… (More)
  • figure 1
  • figure 2
Is this relevant?
2016
2016
177Lu-PSMA-617 radioligand therapy of mCRPC: evaluation criteria of response
Dear Editor, With great interest we read the manuscript by Yadav et al. [1] according toxicity and efficacy of radio ligand… (More)
Is this relevant?
2016
2016
Clinical translation of (177)Lu-labeled PSMA-617: Initial experience in prostate cancer patients.
OBJECTIVE PSMA-617 is reported to exhibit very high binding affinity towards PSMA receptors, over-expressed on prostate cancer… (More)
Is this relevant?
2015
2015
Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer.
UNLABELLED Despite many advances in the past years, the treatment of metastatic prostate cancer still remains challenging. In… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 5
  • figure 6
Is this relevant?